Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes

Diabetes Care

Volumn 38, Issue 11, 2015, Pages e182-e183

  Gaudy, Caroline ^a,b   Clévy, Ćeline ^a   Monestier, Sandrine ^a   Dubois, Noémie ^c   Préau, Yanis ^c   Mallet, Stéphanie ^a   Richard, Marie Aleth ^a,b   Grob, Jean Jacques ^a,b   Valéro, René ^c,d,e   Eliard, Sophie B ^c,d,e,f  

^a TIMONE HOSPITAL   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSERM   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TRIACYLGLYCEROL LIPASE;

ACUTE KIDNEY FAILURE; ADULT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DIABETIC KETOACIDOSIS; DRUG SAFETY; FEMALE; FULMINANT TYPE 1 DIABETES; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABORATORY TEST; METASTATIC MELANOMA; NOTE; POLYDIPSIA; POLYURIA; RETREATMENT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

EID: 84962385750     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1331     Document Type: Note

References (5)

1. Imagawa A, Hanafusa T. Fulminant type 1 diabetesdan important subtype in East Asia. Diabetes Metab Res Rev 2011;27:959-964.
2. Robert C, Ribas A, Wolchok JD, et al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117.
3. Kochupurakkal NM, Kruger AJ, Tripathi S, et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 2014;9: e89561.
4. Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4(1) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 2015;180:452-457.
5. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55-e57.